Our study uncovered a novel KEAP1-independent mechanism for NRF2 activation, suggesting the theoretical feasibility of developing a drug targeting NSUN2 to reduce the overall m5C level and malignant phenotype of cancer cells. The gene discussed is KEAP1; the disease is cancer.